Nicox to refocus DMD treatment

February 19, 2014

Nicox S.A. has decided to re-focus its naproxcinod development efforts, granting an undisclosed financial partner the right to enter into a period of exclusive evaluation to assess the potential development of the drug and of next-generation nitric oxide (NO)-donors outside the ophthalmology area.

 

Sophia Antipolis, France-Nicox S.A. has decided to re-focus its naproxcinod development efforts, granting an undisclosed financial partner the right to enter into a period of exclusive evaluation to assess the potential development of the drug and of next-generation nitric oxide (NO)-donors outside the ophthalmology area.

The evaluation will be entirely funded by the undisclosed partner and will be focused initially on Duchenne muscular dystrophy (DMD). Nicox has granted the undisclosed partner the exclusive right-should the results of the evaluation be satisfactory to the partner-to invest at the end of the evaluation period in the drug and next-generation NO-donors outside ophthalmology through an independent structure.

Nicox will not pursue any other development activities or discussions with third parties related to the drug, which is a Cyclooxygenase-Inhibiting Nitric Oxide-Donating anti-inflammatory candidate.

In October, the European Commission granted Orphan Drug Designation for the drug for the treatment of DMD.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.